Abstract 3081: Precision medicine for patients with advanced small cell lung cancer treated with novel therapeutic agents in a phase I clinical trials unit
Lim J, Harris S, Ameratunga M, Sundar R, Ang J, Collins D, Chénard-Poirier M, Garces A, Kaye S, Lopez J, Banerji U, Bono J, Yap T. Abstract 3081: Precision medicine for patients with advanced small cell lung cancer treated with novel therapeutic agents in a phase I clinical trials unit. Cancer Research 2017, 77: 3081-3081. DOI: 10.1158/1538-7445.am2017-3081.Peer-Reviewed Original ResearchSmall cell lung cancerAdvanced small cell lung cancerNovel therapeutic agentsRECIST SDStable diseasePD-1Partial responsePARP inhibitorsNovel therapiesAmerican Association for Cancer Research annual meetingsNext generation sequencingTherapeutic agentsSignals of antitumor activityNo dose limiting toxicitiesDNA damage repairClinical outcomes of patientsResponse to novel therapiesPD-1 inhibitorsPlatinum-sensitive diseaseRECIST partial responseRECIST stable diseaseDose-limiting toxicityTargeted next generation sequencingTumor molecular profilingPhase I trial